## Edgar Filing: COOK JOSEPH C JR - Form 4

COOK JOSEF Form 4	PH C JR									
June 15, 2009										
FORM	4								PPROVAL	
	- UNITEI	JSIAIE					COMMISSION	OMB Number:	3235-0287	
Check this if no longe subject to Section 16. Form 4 or Form 5	r <b>STATE</b>	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								
obligations may contin <i>See</i> Instruc 1(b).	section 1.		Public Uti ) of the Inv	•	•		of 1935 or Section 40	n		
(Print or Type Re	(sponses)									
1. Name and Ad COOK JOSE	dress of Reportin PH C JR	g Person <u>*</u>	Symbol	Name and T		-	5. Relationship o Issuer			
			[CORT]				(Cheo	ck all applicable	e)	
(Month/I			3. Date of (Month/Da 06/11/20	•	nsaction		X_ Director 10% Owner Officer (give title below) Other (specify below)			
INCORPORA			00/11/20	09						
	(Street)			idment, Date h/Day/Year)	e Original		6. Individual or J Applicable Line) _X_ Form filed by	One Reporting P	erson	
MENLO PAI	RK, CA 94025	5					Person	More than One Ro	eporung	
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	ecurities Ac	quired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executi any		3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock						(2) 1100	304,600	Ι	By Joint Account	
Common Stock							1,130,000	I <u>(1)</u>	By Farview Mgmt Co.	
Common Stock							193,993	Ι	By GRAT	
Common Stock							295,400	Ι	By Joint Account	

Common Stock

240,000

D

#2

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	orDeri Secu Acqu or D (D)	rities uired ispose r. 3, 4	e (A) ed of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(4	<b>A</b> )	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 7							(2)	04/17/2012	Common Stock	50,000
Stock Option (right to buy)	\$ 7							<u>(3)</u>	11/23/2013	Common Stock	25,000
Stock option (right to buy)	\$ 2.7							<u>(4)</u>	12/19/2017	Common Stock	15,000
Warrants	\$ 2.77							03/25/2008	03/24/2015	Common Stock	88,261
Stock Option (right to buy)	\$ 2.23							(5)	06/10/2018	Common Sotck	15,000
Warrants	\$ 2.77							03/25/2008	03/24/2015	Common Stock	31,570
Warrants	\$ 2.77							03/25/2008	03/24/2015	Common Stock	14,402

Warrants	\$ 2.77				03/25/2008	03/24/2015	Common Stock	25,649
Stock option (right to buy)	\$ 0.96	06/11/2009	A	30,000	<u>(6)</u>	06/11/2019	Common Stock	30,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationsh	nips	\$		
r g g	Director	10% Owner	Officer	Other		
COOK JOSEPH C JR C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	Х					
Signatures						
/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact						
<u>**</u> Signature of Reporting Person				Date		

**Explanation of Responses:** 

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are held by Farview Management Co., LLP, of which the reporting person is a general partner.
- (2) Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 4/17/2003 and an additional 1.67% of the total option shares on each monthly anniverary of 4/17/2003 thereafter.
- (3) Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 11/23/2004 and an additional 1.67% of the total option shares on each monthly anniverary of 11/23/2004 thereafter.
- (4) Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest within one year.
- (5) Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year.
- (6) Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2009 so that the entirety of the option grant will vest on or before the date of Corcept's next Annual Meeting of Stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.